Alnylam Pharmaceuticals
ALNY
143.82
-4.00
-2.71%
Alnylam Pharmaceuticals
US · ALNY
#627 by market cap
Listed 1970
143.82
-4.00
-2.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 104.22% -0.09pp
- Institutions
- 950 -3
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund91.35%
Hedge Fund4.50%
Public Company3.56%
Sovereign Wealth Fund1.77%
Government Pension Fund1.52%
Private Company0.84%
VC/PE Fund0.26%
Insurance Company0.20%
Individual/Insider0.18%
Top holders as of 2026-09-30
Capital Research
18.57% · 24.88M sh
FMR
9.00% · 12.05M sh
BlackRock
8.23% · 11.02M sh
T. Rowe Price Group, Inc.
8.03% · 10.76M sh
Vanguard Capital Management, LLC
5.14% · 6.88M sh
Vanguard Portfolio Management, LLC
5.00% · 6.70M sh
Baillie Gifford
4.10% · 5.49M sh
State Street Global Advisors
2.85% · 3.82M sh
Wellington Management Group
2.60% · 3.48M sh
Geode Capital Management, LLC
1.93% · 2.59M sh
Invesco Capital Management LLC
2.59% · 3.47M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Phillip Sharp | Co-Founder, Member of the Scientific Advisory Board | 0.20% |
| Yvonne Greenstreet | Chief Executive Officer | 0.04% |
| Jeffrey Poulton | Chief Financial Officer | 0.03% |
| David E. Pyott | Independent Director | 0.02% |
| Amy W. Schulman | Independent Chairperson | 0.02% |
| Michael Bonney | Former Non-Independent Director | 0.01% |
| Tolga Tanguler | Former Executive VP & Chief Commercialization Officer | 0.01% |
| Pushkal Garg | Executive VP & Chief Research & Development Officer | 0.01% |
| Kevin Fitzgerald | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development | 0.01% |
| Melissa McLaughlin | Chief Human Resources Officer | 0.01% |
| Bryan Supran | Chief Legal Officer | 0.01% |
| Dennis Ausiello | Member of the Scientific Advisory Board & Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | David E. Pyott | Independent Director | Derivative Exercise and Retained | +3,780 | $71.99 |
| 2026-11-09 | Charles Sigal | Independent Director | Open Market Acquisition | +1,600 | $152.25 |
| 2026-11-08 | Amy W. Schulman | Independent Chairperson | Open Market Acquisition | +1,910 | $156.82 |
| 2026-10-01 | Bryan Supran | Chief Legal Officer | Open Market Disposition | -1,758 | $226.88 |
| 2026-10-01 | Bryan Supran | Chief Legal Officer | Intent to Sell (Form 144) | -1,758 | $226.88 |
| 2026-09-18 | Yvonne Greenstreet | Chief Executive Officer | Other Acquisition | +107 | -- |
| 2026-05-31 | David E. Pyott | Independent Director | Derivative Exercise and Sale | -3,830 | $297.71–302.65 |
| 2026-05-31 | Benjamin Cravatt | Director | Other Derivative Acquisition | +4,393 | $295.63 |
| 2026-05-19 | Peter Kellogg | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Peter Kellogg | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | David E. Pyott | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | David E. Pyott | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Charles Sigal | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Charles Sigal | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Margaret Hamburg | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Margaret Hamburg | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Amy W. Schulman | Independent Chairperson | Other Acquisition | +838 | -- |
| 2026-05-19 | Amy W. Schulman | Independent Chairperson | Other Derivative Acquisition | +1,802 | $298.48 |
| 2026-05-19 | Dennis Ausiello | Member of the Scientific Advisory Board & Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Dennis Ausiello | Member of the Scientific Advisory Board & Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Alnylam Pharmaceuticals discussion 0 comments